Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.

Hemolytic uremic syndrome (HUS) is a disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Recent studies have identified a factor H-associated form of HUS, caused by gene mutations that cluster in the C-terminal region of the complement regulator factor H. Here we report how three mutations (E1172Stop, R1210C, and R1215G; each of the latter two identified in three independent cases from different, unrelated families) affect protein function. All three mutations cause reduced binding to the central complement component C3b/C3d to heparin, as well as to endothelial cells. These defective features of the mutant factor H proteins explain progression of endothelial cell and microvascular damage in factor H-associated genetic HUS and indicate a protective role of factor H for tissue integrity during thrombus formation.

[1]  J. Goodship,et al.  Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  S. Perkins,et al.  Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding site. , 2002, Journal of molecular biology.

[3]  S. Meri,et al.  Each of the three binding sites on complement factor H interacts with a distinct site on C3b. , 2000, The Journal of biological chemistry.

[4]  S. Schulman,et al.  The pathogenesis and treatment of hemolytic uremic syndrome. , 1998, Journal of the American Society of Nephrology : JASN.

[5]  M. Pangburn,et al.  Cutting Edge: Localization of the Host Recognition Functions of Complement Factor H at the Carboxyl-Terminal: Implications for Hemolytic Uremic Syndrome1 , 2002, The Journal of Immunology.

[6]  J. Goodship,et al.  Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. , 2001, American journal of human genetics.

[7]  R. Chesney,et al.  Hemolytic uremic syndrome in families. , 1975, The New England journal of medicine.

[8]  P. Zipfel,et al.  Mapping of the domains required for decay acceleration activity of the human factor H‐like protein 1 and factor H , 1996, European journal of immunology.

[9]  M. Pangburn,et al.  Kinetic and thermodynamic analysis of the control of C3b by the complement regulatory proteins factors H and I. , 1983, Biochemistry.

[10]  P. Zipfel,et al.  Identification of the second heparin-binding domain in human complement factor H. , 1998, Journal of immunology.

[11]  R. Thompson,et al.  Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. , 1981, Clinical and experimental immunology.

[12]  P. Mathieson.  Complement factor H and haemolytic uraemic syndrome , 2002, The Lancet.

[13]  M. Pangburn,et al.  Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Remuzzi,et al.  The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. , 2001, Journal of the American Society of Nephrology : JASN.

[15]  S. Meri,et al.  Factor H and disease: a complement regulator affects vital body functions. , 1999, Molecular immunology.

[16]  D. Pérez-Caballero,et al.  Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. , 2002, American journal of human genetics.

[17]  R. Discipio,et al.  Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18). , 1998, Journal of immunology.

[18]  J. Goodship,et al.  Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. , 2000, American journal of human genetics.

[19]  G. Carlos,et al.  The hemolytic-uremic syndrome , 1964 .

[20]  K. Drummond,et al.  The hemolytic-uremic syndrome is a syndrome. , 1978, The New England journal of medicine.

[21]  D. Pérez-Caballero,et al.  Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. , 2001, American journal of human genetics.

[22]  M. Young,et al.  Factor H Binding to Bone Sialoprotein and Osteopontin Enables Tumor Cell Evasion of Complement-mediated Attack* , 2000, The Journal of Biological Chemistry.

[23]  S. Meri,et al.  The factor H protein family. , 1999, Immunopharmacology.

[24]  R. Marks,et al.  Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. , 1998, Journal of immunology.

[25]  D. Devine,et al.  Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Lublin,et al.  Identification of complement regulatory domains in human factor H. , 1995, Journal of immunology.

[27]  P. Zipfel,et al.  The baculovirus expression vector pBSV-8His directs secretion of histidine-tagged proteins. , 1995, Gene.

[28]  H. Colten,et al.  Human Factor H Deficiency , 1997, The Journal of Biological Chemistry.

[29]  G. Remuzzi,et al.  Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. , 1999, Journal of the American Society of Nephrology : JASN.

[30]  P. Zipfel.  Hemolytic uremic syndrome: how do factor H mutants mediate endothelial damage? , 2001, Trends in immunology.

[31]  B. Nilsson,et al.  Complement C3b interactions studied with surface plasmon resonance technique. , 2001, International immunopharmacology.

[32]  J. Goodship,et al.  Genetic studies into inherited and sporadic hemolytic uremic syndrome. , 1998, Kidney international.

[33]  P. Zipfel,et al.  Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1. , 1995, Journal of immunology.

[34]  P. Zipfel,et al.  Complement factor H and hemolytic uremic syndrome. , 2001, International immunopharmacology.

[35]  K. Whaley,et al.  Modulation of the alternative complement pathways by beta 1 H globulin , 1976, The Journal of experimental medicine.

[36]  P. Lambert,et al.  The complement system in hemolytic-uremic syndrome in childhood. , 1980, Clinical nephrology.

[37]  P. Zipfel,et al.  The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. , 1998, The Biochemical journal.